Skip to Content
Merck
All Photos(1)

Documents

MAB381

Sigma-Aldrich

Anti-Myelin Basic Protein Antibody, a.a. 119-131, clone 2

culture supernatant, clone 2, Chemicon®

Synonym(s):

MBP

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

mouse

Quality Level

antibody form

culture supernatant

antibody product type

primary antibodies

clone

2, monoclonal

species reactivity

bovine, sheep, human, rat, rabbit, guinea pig

manufacturer/tradename

Chemicon®

technique(s)

ELISA: suitable
immunohistochemistry: suitable

isotype

IgG1

UniProt accession no.

shipped in

dry ice

target post-translational modification

unmodified

Gene Information

human ... MBP(4155)
rat ... Mbp(24547)

Specificity

Reacts with MBP from human, bovine, rabbit, guinea pig, rat, and sheep. The epitope appears to be located in the region of residues 119-131.

Immunogen

Bovine myelin basic protein.
Epitope: a.a. 119-131

Application

Anti-Myelin Basic Protein Antibody, a.a. 119-131, clone 2 is an antibody against Myelin Basic Protein for use in ELISA, IH.
Immunohistochemistry - frozen sections

ELISA

Optimal working dilutions must be determined by end user.
Research Category
Neuroscience
Research Sub Category
Neuronal & Glial Markers

Neurochemistry & Neurotrophins

Physical form

Tissue culture supernatant. Liquid in 0.2M Tris/HCl, pH 7.4 with 5-10% fetal calf serum and 0.09% sodium azide.

Storage and Stability

Maintain at -20°C for up to 12 months in undiluted aliquots. Avoid repeated freeze-thaw cycles.

Important Note: During shipment, small volumes of product will occasionally become entrapped in the seal of the product vial. For products with volumes of 200 μL or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the container′s cap.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

WGK 3


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Central Nervous System and Peripheral Expression of CCL19, CCL21 and Their Receptor CCR7 in Experimental Model of Multiple Sclerosis.
Bielecki, B; Jatczak-Pawlik, I; Wolinski, P; Bednarek, A; Glabinski, A
Archivum Immunologiae et Therapiae Experimentalis null
Jens Kuhle et al.
The New England journal of medicine, 356(4), 371-378 (2007-01-26)
Patients with a single episode of neurologic dysfunction and brain magnetic resonance imaging (MRI) scans suggestive of multiple sclerosis are at high risk for clinically definite multiple sclerosis, but the outcome for individual patients is unpredictable. An increased risk of
Kelly Q Zhou et al.
Pediatric research, 88(1), 48-56 (2019-06-25)
Therapeutic hypothermia is partially protective for neonatal hypoxic-ischemic encephalopathy (HIE). Damage to the white matter tracts is highly associated with adverse outcomes after HIE, but the effectiveness and optimal duration of hypothermia to attenuate axonal injury are unclear. Near-term fetal
Guido Wassink et al.
Brain communications, 3(3), fcab172-fcab172 (2021-08-20)
Therapeutic hypothermia for hypoxic-ischaemic encephalopathy provides partial white matter protection. Recombinant erythropoietin reduces demyelination after hypoxia-ischaemia, but it is unclear whether adjunct erythropoietin treatment can further improve outcomes after therapeutic hypothermia. Term-equivalent fetal sheep received sham-ischaemia (n = 9) or cerebral ischaemia
Jan Storek et al.
Clinical immunology (Orlando, Fla.), 113(3), 285-298 (2004-10-28)
To ascertain the consequences of severe leukopenia and the tempo of recovery, we studied the immunity of 56 adult patients treated for multiple sclerosis or systemic sclerosis with autologous CD34 cell transplantation using extremely lymphoablative conditioning. NK cell, monocyte, and

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service